Tracking cystic fibrosis in young children
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tracks the natural course of cystic fibrosis in young children (under 6) and healthy babies over time. It aims to understand how the disease changes in the era of modern treatments, which could help improve care and guide future therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Children with cystic fibrosis (CF) who are either newly diagnosed through newborn screening (or have two CF-causing mutations) and are aged 0 to 6 when the study begins.
- Alternatively, healthy infants without CF can join as a comparison group.
- A diagnosis must be confirmed, for example, by a sweat chloride test measuring over 60 or by a genetic test showing two CF mutations.
- Children must be able to attend study visits and complete the required assessments.
- Children with serious health issues unrelated to CF (such as inflammatory bowel disease or extreme prematurity) might not be eligible, as these could affect study results.
- For the healthy control group, children cannot be carriers of CF-related genes or have chronic medical, stomach, or liver conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls newly diagnosed infants with cystic fibrosis to follow them during “precision medicine” care. It may help doctors better understand which treatments and monitoring work best, especially before certain infections develop.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study looks at how where your body stores fat may be linked to changes in metabolism and lung function over time in people with cystic fibrosis. It also compares results with healthy people similar in age, sex, and body size to understand the differences better.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.